FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383313257> ?p ?o ?g. }

• W4383313257 abstract "Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated clinical benefit for patients with solid tumors bearing germline or somatic alterations in DNA damage response (DDR) genes. Somatic alterations in DDR genes are common in advanced urothelial cancer, raising the possibility that PARP inhibition may confer therapeutic benefit in a molecularly selected subgroup of patients with metastatic urothelial cancer (mUC).This single-arm, open-label, multi-institutional, investigator-initiated phase II study evaluated the antitumor activity of olaparib 300 mg twice a day in participants with mUC harboring somatic DDR alterations. Patients had progressed despite previous platinum-based chemotherapy, or were cisplatin-ineligible, and harbored somatic alterations in at least one of a prespecified list of DDR genes. The primary end point was objective response rate; secondary end points were safety, progression-free survival (PFS), and overall survival (OS).Overall, 19 patients with mUC were enrolled and received olaparib; the trial closed early before slow accrual. The median age was 66 years (range, 45-82). Nine patients (47.4%) had received previous cisplatin chemotherapy. Ten patients (52.6%) had alterations in homologous recombination (HR) genes: eight patients (42.1%) had pathogenic BRCA2 mutations and two patients carried alterations in other HR genes. No patients achieved a partial response although six patients achieved stable disease lasting 2.13-16.1 months (median, 7.69). The median PFS was 1.9 months (range, 0.8-16.1), and the median OS was 9.5 months (range, 1.5-22.1).Single-agent olaparib showed limited antitumor activity in patients with mUC and DDR alterations, which may be related to poorly characterized functional implications of particular DDR alterations and/or cross-resistance with platinum-based chemotherapy in a disease where such therapy represents standard first-line treatment." @default.
• W4383313257 created "2023-07-07" @default.
• W4383313257 creator A5000198604 @default.
• W4383313257 creator A5011207841 @default.
• W4383313257 creator A5013942253 @default.
• W4383313257 creator A5018275141 @default.
• W4383313257 creator A5018398274 @default.
• W4383313257 creator A5025635505 @default.
• W4383313257 creator A5032258125 @default.
• W4383313257 creator A5044979250 @default.
• W4383313257 creator A5057063597 @default.
• W4383313257 creator A5073593424 @default.
• W4383313257 creator A5083920381 @default.
• W4383313257 date "2023-07-01" @default.
• W4383313257 modified "2023-10-13" @default.
• W4383313257 title "Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations" @default.
• W4383313257 cites W1893588230 @default.
• W4383313257 cites W1974722941 @default.
• W4383313257 cites W2068523052 @default.
• W4383313257 cites W2071433338 @default.
• W4383313257 cites W2101562875 @default.
• W4383313257 cites W2123454509 @default.
• W4383313257 cites W2131178190 @default.
• W4383313257 cites W2199466904 @default.
• W4383313257 cites W2235405584 @default.
• W4383313257 cites W2432541865 @default.
• W4383313257 cites W2509895884 @default.
• W4383313257 cites W2559804019 @default.
• W4383313257 cites W2802899563 @default.
• W4383313257 cites W2804391526 @default.
• W4383313257 cites W2883374837 @default.
• W4383313257 cites W2989894179 @default.
• W4383313257 cites W3020771563 @default.
• W4383313257 cites W3036701611 @default.
• W4383313257 cites W3087464965 @default.
• W4383313257 cites W3164048465 @default.
• W4383313257 cites W4212895261 @default.
• W4383313257 cites W4213073706 @default.
• W4383313257 cites W4213209893 @default.
• W4383313257 cites W4236289131 @default.
• W4383313257 cites W4379281896 @default.
• W4383313257 cites W2904125198 @default.
• W4383313257 doi "https://doi.org/10.1200/po.23.00095" @default.
• W4383313257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37410974" @default.
• W4383313257 hasPublicationYear "2023" @default.
• W4383313257 type Work @default.
• W4383313257 citedByCount "2" @default.
• W4383313257 countsByYear W43833132572023 @default.
• W4383313257 crossrefType "journal-article" @default.
• W4383313257 hasAuthorship W4383313257A5000198604 @default.
• W4383313257 hasAuthorship W4383313257A5011207841 @default.
• W4383313257 hasAuthorship W4383313257A5013942253 @default.
• W4383313257 hasAuthorship W4383313257A5018275141 @default.
• W4383313257 hasAuthorship W4383313257A5018398274 @default.
• W4383313257 hasAuthorship W4383313257A5025635505 @default.
• W4383313257 hasAuthorship W4383313257A5032258125 @default.
• W4383313257 hasAuthorship W4383313257A5044979250 @default.
• W4383313257 hasAuthorship W4383313257A5057063597 @default.
• W4383313257 hasAuthorship W4383313257A5073593424 @default.
• W4383313257 hasAuthorship W4383313257A5083920381 @default.
• W4383313257 hasConcept C104317684 @default.
• W4383313257 hasConcept C121608353 @default.
• W4383313257 hasConcept C126322002 @default.
• W4383313257 hasConcept C134305767 @default.
• W4383313257 hasConcept C143998085 @default.
• W4383313257 hasConcept C182979987 @default.
• W4383313257 hasConcept C2776694085 @default.
• W4383313257 hasConcept C2778239845 @default.
• W4383313257 hasConcept C2779138821 @default.
• W4383313257 hasConcept C2779962180 @default.
• W4383313257 hasConcept C502942594 @default.
• W4383313257 hasConcept C54355233 @default.
• W4383313257 hasConcept C71924100 @default.
• W4383313257 hasConcept C82381507 @default.
• W4383313257 hasConcept C86803240 @default.
• W4383313257 hasConceptScore W4383313257C104317684 @default.
• W4383313257 hasConceptScore W4383313257C121608353 @default.
• W4383313257 hasConceptScore W4383313257C126322002 @default.
• W4383313257 hasConceptScore W4383313257C134305767 @default.
• W4383313257 hasConceptScore W4383313257C143998085 @default.
• W4383313257 hasConceptScore W4383313257C182979987 @default.
• W4383313257 hasConceptScore W4383313257C2776694085 @default.
• W4383313257 hasConceptScore W4383313257C2778239845 @default.
• W4383313257 hasConceptScore W4383313257C2779138821 @default.
• W4383313257 hasConceptScore W4383313257C2779962180 @default.
• W4383313257 hasConceptScore W4383313257C502942594 @default.
• W4383313257 hasConceptScore W4383313257C54355233 @default.
• W4383313257 hasConceptScore W4383313257C71924100 @default.
• W4383313257 hasConceptScore W4383313257C82381507 @default.
• W4383313257 hasConceptScore W4383313257C86803240 @default.
• W4383313257 hasIssue "7" @default.
• W4383313257 hasLocation W43833132571 @default.
• W4383313257 hasLocation W43833132572 @default.
• W4383313257 hasOpenAccess W4383313257 @default.
• W4383313257 hasPrimaryLocation W43833132571 @default.
• W4383313257 hasRelatedWork W2147619880 @default.
• W4383313257 hasRelatedWork W2561005546 @default.
• W4383313257 hasRelatedWork W2973954290 @default.
• W4383313257 hasRelatedWork W3023457002 @default.
• W4383313257 hasRelatedWork W3121450744 @default.

• next